Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-92
Last updated

Report documents

  1. Extract of dossier assessment

    Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 312 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 312 kB, EN, not accessible)

  2. Dossier assessment

    Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 459 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 459 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A22-92
Commission
Commission awarded on 29.08.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-91
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-116
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-16
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-15
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-08
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-66
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-38
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page